A high-level overview of AstraZeneca PLC (AZNCF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
AstraZeneca PLC AZN:LSE Actions Health CarePharmaceuticals and Biotechnology Price (GBX)10,982.00 Today's Change-6.00 / -0.05% Shares traded3.04m 1 Year change+0.75% Beta0.3752 Data delayed at least 20 minutes, as of Jan 10 2025 14:42 GMT....
A high-level overview of AstraZeneca PLC (AZN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £1...
Latest AstraZeneca PLC (AZNA:VIE) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
AstraZeneca carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector includeArcturus TherapeuticsARCT,BioventusBVSandFulcrum TherapeuticsFULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can seethe complete list of today’s Zacks #1 Rank stocks...
So we have to -- the assumption is the share of sales is not going to be the 20% we saw a few years ago. We are at 12%, 13% today, and the rest of the world will grow much more. So I guess what I'm saying is we will navigate this difficult period, and we think we can...
Despite the hefty cost of this acquisition, which is roughly 84% greater than its 30-day volume weight average price of $11.37 per share, AstraZeneca implies that the acquisition is a significant step forward for the company’s oncology portfolio....
30 that Wang was under official investigation, a disclosure that has depressed the Cambridge-based company’s share price [LON: AZN] by about 7 percent since then. The stock was trading 3 percent lower at GBP107.15 (USD139.15) as of 12.29 p.m. local time in London today. In April ...
Results were presented today in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021. At a prespecified interim analysis of DESTINY-Breast03, ENHERTU provided a 72% reduction in the risk of disease p...